SynthesisDiabetes, obesity & metabolism2012

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.

T Ridge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.